InFlectis BioScience is a private drug discovery company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Unfolded Protein Response (UPR) to treat misfolding protein disorders such as neurodegenerative and age-related diseases.

Latest News

Anticipated Milestones

  • First in Human by mid-2018